<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363144">
  <stage>Registered</stage>
  <submitdate>12/10/2012</submitdate>
  <approvaldate>17/10/2012</approvaldate>
  <actrnumber>ACTRN12612001108808</actrnumber>
  <trial_identification>
    <studytitle>The administration of vitamin B12 to people with type 2 diabetes (T2DM) on long term metformin therapy</studytitle>
    <scientifictitle>The effect of oral vitamin B12 supplementation vs intramuscular injection on serum vitamin B12 level in people with type 2 diabetes on metformin therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 diabetes</healthcondition>
    <healthcondition>Vitamin B12 deficiency</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Methylcobalamin 1000mcg tablets 3 month course of 1 x 1000mcg tablet per day. Rescreen at 3 months, if levels not above 220 mmol/l then re-treat with the same treatment.</interventions>
    <comparator>1 x 1000mcg methylcobalamin intramuscular injection - current standard treatment. Rescreen at 3 months, if levels not above 220 mmol/l then re-treat with the same treatment.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>serum vitamin B12 level</outcome>
      <timepoint>3 and 6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>neuropathy screening using Michigan neuropathy screening questionnaire</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Type 2 diabetes
Metformin therapy
vitamin b12 levels below 220mmol/l</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnant or breastfeeding
Existing treated megaloblastic anaemia</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants will be stratified by B12 level to ensure an even number of those with low and deficient status in each group, then randomised by sealed envelope.</concealment>
    <sequence>Randomisation numbers will be computer generated by a random numbers progamme and placed in sealed envelopes. The next envelope on the pile will be given sequentially to participants.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>20/01/2013</anticipatedstartdate>
    <actualstartdate>15/02/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>4/02/2014</actualenddate>
    <samplesize>140</samplesize>
    <actualsamplesize>34</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Capital and Coast Health</primarysponsorname>
    <primarysponsoraddress>Private bag 7902
Wellington 6021</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Otago</fundingname>
      <fundingaddress>PO Box 7343
Wellington 6021</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Metformin, the most common hypoglycaemic agent used in type 2 diabetes, is associated with reduced vitamin B12 status.  This study will determine the prevalence of B12 deficiency (&lt;150pmol/l) and low B12 status (150-220 pmol/l) in a NZ population with Type 2 Diabetes taking metformin. We will then assess the best replacement regimen in this group. Those with low or deficient B12 status will be randomised to either intra-muscular injection OR over the counter oral B12 tablets. B12 status will be assessed at 3 and 6 months, with a second treatment administered if levels have not returned to normal after the 3 month check.</summary>
    <trialwebsite>none</trialwebsite>
    <publication>Haeusler S, Parry-Strong A, Krebs JD. The prevalence of low vitamin B12 status in people with type 2 diabetes receiving metformin therapy in New Zealanda clinical audit. 2014; 127 (1404) ISSN 1175-8716</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Health and Disability Ethics Committee Central</ethicname>
      <ethicaddress>Ministry of Health
No 1 The Terrace
PO Box 5013
Wellington 6021</ethicaddress>
      <ethicapprovaldate>18/01/2013</ethicapprovaldate>
      <hrec>12/CEN/65</hrec>
      <ethicsubmitdate>13/11/2012</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Amber Parry Strong</name>
      <address>Capital and Coast Health
Diabetes Research
Private Bag 7902
Wellington 6021</address>
      <phone>+6448062458</phone>
      <fax />
      <email>amber.parry-strong@ccdhb.org.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Amber Parry Strong</name>
      <address>Capital and Coast Health
Diabetes Research
Private Bag 7902
Wellington 6021</address>
      <phone>+6448062458</phone>
      <fax />
      <email>amber.parry-strong@ccdhb.org.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jeremy Krebs</name>
      <address>Capital and Coast Health Diabetes Research Private Bag 7902 Wellington 6021 </address>
      <phone>+6448062458 </phone>
      <fax />
      <email>jeremy.krebs@ccdhb.org.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>